Company Filing History:
Years Active: 2017
Title: Jens Fleschhut: Innovator in Transdermal Therapeutic Systems
Introduction
Jens Fleschhut is a notable inventor based in Holzkirchen, Germany. He has made significant contributions to the field of transdermal therapeutic systems, particularly through his innovative work involving buprenorphine. His expertise and dedication to advancing medical technology have positioned him as a key figure in his industry.
Latest Patents
Fleschhut holds a patent for a transdermal therapeutic system comprising buprenorphine. This invention focuses on a method of manufacturing a transdermal therapeutic system (TTS) that allows for the effective transdermal administration of buprenorphine and its analogues. The TTS is specifically designed for analgesic purposes, providing a novel approach to pain management. The system includes a drug delivery composition that combines buprenorphine with an adhesive component, which consists of a mixture of crosslinked and non-crosslinked acrylic polymers, along with a penetration enhancer that features a keto acid. This innovative approach enhances the efficacy of buprenorphine delivery through the skin.
Career Highlights
Jens Fleschhut is associated with Hexal AG, a prominent company in the pharmaceutical industry. His work at Hexal AG has allowed him to collaborate with other talented professionals and contribute to the development of advanced therapeutic solutions. His patent reflects his commitment to improving patient care through innovative drug delivery systems.
Collaborations
Fleschhut has worked alongside colleagues such as Susanne Feinaeugle and Karin Lauer. Their collaborative efforts have played a crucial role in the advancement of their projects and the successful development of new therapeutic systems.
Conclusion
Jens Fleschhut's contributions to the field of transdermal therapeutic systems highlight his innovative spirit and dedication to improving healthcare solutions. His patent for a transdermal system comprising buprenorphine exemplifies the potential for advancements in pain management.